January 16th, 2020 | 11:53 CET
Aurora Cannabis, Canopy Growth, EXMceuticals - Profits with turnaround
2019 was not a good year for investors in the cannabis sector with a long-term approach. After a never-ending rally in the years before, the party was over. However, the price capers can also be an opportunity to enter companies that are now one experience richer than they were a year ago in a champagne mood.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
CA30207T1049 , CA05156X1087 , CA1380351009
Table of contents:
"[...] We are a producer and distributor of medicinal products and thus cover a crucial step in the value chain, especially within the cannabis industry. [...]" Philip Schetter, CEO, Cantourage Group SE
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Share price recovery has begun
The shares of Aurora Cannabis changed hands in March 2019 in the peak at 13.67 CAD - the year before the historic high was even 16.24 CAD. What then followed was a flawless trend towards CAD 0.00, which ended last week at a low of CAD 1.96.
On yesterday's trading day, the share was traded at the closing price of 2.68 CAD. A return of over 36% within one week would have been theoretically possible. The market value of Aurora Cannabis is currently CAD 2.93 billion.
Clearly caught up from the low
With yesterday's closing price of 32.46 CAD and a current market value of 11.31 billion CAD, Canopy Growth is one of the top companies in the cannabis industry. In 2018 the shares changed hands at a peak of 76.68 CAD and last year the peak was 70.99 CAD.
The rapid price losses in phases ended in November at 18.23 CAD. Since then the share price has regained ground and hypothetically a performance of over 78% would have been possible from the low until yesterday.
Starting point for turnaround
For a long time, the stock of the newcomer EXMceuticals was excluded from the price capers of the well-known names. Although the share price was volatile, it nevertheless moved sideways between 0.87 CAD and 1.72 CAD. But in November 2019 the share price dropped further and was traded at CAD 0.45 at the beginning of 2020.
It now looks like it has bottomed out and could become the starting point for a turnaround. At yesterday's closing price of CAD 0.50, the company has a market value of CAD 18.28 million. The company yesterday announced further details of its development, it is continuing to make progress operationally.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
